Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger

Sharon X. Liang, Micheal Pearl, Shu Liang, Li Xiang, Lin Jia, Binlie Yang, Oluwole Fadare, Peter E. Schwartz, Setsuko K Chambers, Beihua Kong, Wenxin - Zheng

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A comparative study between endometrial serous carcinoma (ESC) and endometrial endometrioid carcinoma (EEC) was performed to determine whether a personal history of breast cancer is a risk factor for ESC in women aged ≤55 yr. Study subjects consisted of 348 women who were diagnosed with ESC and 830 comparison subjects who had EEC. Variables studied included age at diagnosis, a history of breast cancer, tamoxifen therapy, hormonal replacement therapy and smoking history. Overall, 19.4% of women with ESC had a history of breast cancer, which was significantly higher than that of 3% in comparison subjects. Among the study subjects, the incidence of a prior breast cancer was significantly higher in patients who were 55 yr of age or younger (41.5%) than those who were older than 55 yr (16%). The statistical significance of both of the aforementioned comparisons was independent of tamoxifen usage on multivariate analyses. The mean time interval between prior breast cancer and endometrial cancer was 92.5 mo (range 7-240 mo) in the study group and 79 mo (range 7-192 mo) in the comparison group. For the whole cohort and individual subgroups (ESC, EEC, a;circ55 yr and >55 yr), a personal history of breast cancer did not adversely affect the patient outcomes, which was largely dependent on standard clinicopathologic parameters such as International Federation of Gynecology and Obstetrics stage, as has previously been demonstrated. These findings suggest that a personal history of breast cancer may be a significant risk factor for the development of ESC in women aged ≤55 yr. Further studies are needed to clarify the relationship between these two cancers in this age group and whether this increased risk is reflective of a genetic predisposition.

Original languageEnglish (US)
Pages (from-to)763-770
Number of pages8
JournalInternational Journal of Cancer
Volume128
Issue number4
DOIs
StatePublished - Feb 15 2011

Fingerprint

Endometrial Neoplasms
Breast Neoplasms
Endometrioid Carcinoma
Tamoxifen
Genetic Predisposition to Disease
Gynecology
Obstetrics
Cohort Studies
Multivariate Analysis
Age Groups
Smoking
History
Therapeutics

Keywords

  • breast cancer
  • endometrial serous carcinoma
  • high risk
  • uterine papillary serous carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. / Liang, Sharon X.; Pearl, Micheal; Liang, Shu; Xiang, Li; Jia, Lin; Yang, Binlie; Fadare, Oluwole; Schwartz, Peter E.; Chambers, Setsuko K; Kong, Beihua; Zheng, Wenxin -.

In: International Journal of Cancer, Vol. 128, No. 4, 15.02.2011, p. 763-770.

Research output: Contribution to journalArticle

Liang, Sharon X. ; Pearl, Micheal ; Liang, Shu ; Xiang, Li ; Jia, Lin ; Yang, Binlie ; Fadare, Oluwole ; Schwartz, Peter E. ; Chambers, Setsuko K ; Kong, Beihua ; Zheng, Wenxin -. / Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. In: International Journal of Cancer. 2011 ; Vol. 128, No. 4. pp. 763-770.
@article{97b2a8a6f2c64a4995fb64c43489895b,
title = "Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger",
abstract = "A comparative study between endometrial serous carcinoma (ESC) and endometrial endometrioid carcinoma (EEC) was performed to determine whether a personal history of breast cancer is a risk factor for ESC in women aged ≤55 yr. Study subjects consisted of 348 women who were diagnosed with ESC and 830 comparison subjects who had EEC. Variables studied included age at diagnosis, a history of breast cancer, tamoxifen therapy, hormonal replacement therapy and smoking history. Overall, 19.4{\%} of women with ESC had a history of breast cancer, which was significantly higher than that of 3{\%} in comparison subjects. Among the study subjects, the incidence of a prior breast cancer was significantly higher in patients who were 55 yr of age or younger (41.5{\%}) than those who were older than 55 yr (16{\%}). The statistical significance of both of the aforementioned comparisons was independent of tamoxifen usage on multivariate analyses. The mean time interval between prior breast cancer and endometrial cancer was 92.5 mo (range 7-240 mo) in the study group and 79 mo (range 7-192 mo) in the comparison group. For the whole cohort and individual subgroups (ESC, EEC, a;circ55 yr and >55 yr), a personal history of breast cancer did not adversely affect the patient outcomes, which was largely dependent on standard clinicopathologic parameters such as International Federation of Gynecology and Obstetrics stage, as has previously been demonstrated. These findings suggest that a personal history of breast cancer may be a significant risk factor for the development of ESC in women aged ≤55 yr. Further studies are needed to clarify the relationship between these two cancers in this age group and whether this increased risk is reflective of a genetic predisposition.",
keywords = "breast cancer, endometrial serous carcinoma, high risk, uterine papillary serous carcinoma",
author = "Liang, {Sharon X.} and Micheal Pearl and Shu Liang and Li Xiang and Lin Jia and Binlie Yang and Oluwole Fadare and Schwartz, {Peter E.} and Chambers, {Setsuko K} and Beihua Kong and Zheng, {Wenxin -}",
year = "2011",
month = "2",
day = "15",
doi = "10.1002/ijc.25395",
language = "English (US)",
volume = "128",
pages = "763--770",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger

AU - Liang, Sharon X.

AU - Pearl, Micheal

AU - Liang, Shu

AU - Xiang, Li

AU - Jia, Lin

AU - Yang, Binlie

AU - Fadare, Oluwole

AU - Schwartz, Peter E.

AU - Chambers, Setsuko K

AU - Kong, Beihua

AU - Zheng, Wenxin -

PY - 2011/2/15

Y1 - 2011/2/15

N2 - A comparative study between endometrial serous carcinoma (ESC) and endometrial endometrioid carcinoma (EEC) was performed to determine whether a personal history of breast cancer is a risk factor for ESC in women aged ≤55 yr. Study subjects consisted of 348 women who were diagnosed with ESC and 830 comparison subjects who had EEC. Variables studied included age at diagnosis, a history of breast cancer, tamoxifen therapy, hormonal replacement therapy and smoking history. Overall, 19.4% of women with ESC had a history of breast cancer, which was significantly higher than that of 3% in comparison subjects. Among the study subjects, the incidence of a prior breast cancer was significantly higher in patients who were 55 yr of age or younger (41.5%) than those who were older than 55 yr (16%). The statistical significance of both of the aforementioned comparisons was independent of tamoxifen usage on multivariate analyses. The mean time interval between prior breast cancer and endometrial cancer was 92.5 mo (range 7-240 mo) in the study group and 79 mo (range 7-192 mo) in the comparison group. For the whole cohort and individual subgroups (ESC, EEC, a;circ55 yr and >55 yr), a personal history of breast cancer did not adversely affect the patient outcomes, which was largely dependent on standard clinicopathologic parameters such as International Federation of Gynecology and Obstetrics stage, as has previously been demonstrated. These findings suggest that a personal history of breast cancer may be a significant risk factor for the development of ESC in women aged ≤55 yr. Further studies are needed to clarify the relationship between these two cancers in this age group and whether this increased risk is reflective of a genetic predisposition.

AB - A comparative study between endometrial serous carcinoma (ESC) and endometrial endometrioid carcinoma (EEC) was performed to determine whether a personal history of breast cancer is a risk factor for ESC in women aged ≤55 yr. Study subjects consisted of 348 women who were diagnosed with ESC and 830 comparison subjects who had EEC. Variables studied included age at diagnosis, a history of breast cancer, tamoxifen therapy, hormonal replacement therapy and smoking history. Overall, 19.4% of women with ESC had a history of breast cancer, which was significantly higher than that of 3% in comparison subjects. Among the study subjects, the incidence of a prior breast cancer was significantly higher in patients who were 55 yr of age or younger (41.5%) than those who were older than 55 yr (16%). The statistical significance of both of the aforementioned comparisons was independent of tamoxifen usage on multivariate analyses. The mean time interval between prior breast cancer and endometrial cancer was 92.5 mo (range 7-240 mo) in the study group and 79 mo (range 7-192 mo) in the comparison group. For the whole cohort and individual subgroups (ESC, EEC, a;circ55 yr and >55 yr), a personal history of breast cancer did not adversely affect the patient outcomes, which was largely dependent on standard clinicopathologic parameters such as International Federation of Gynecology and Obstetrics stage, as has previously been demonstrated. These findings suggest that a personal history of breast cancer may be a significant risk factor for the development of ESC in women aged ≤55 yr. Further studies are needed to clarify the relationship between these two cancers in this age group and whether this increased risk is reflective of a genetic predisposition.

KW - breast cancer

KW - endometrial serous carcinoma

KW - high risk

KW - uterine papillary serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=78650617304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650617304&partnerID=8YFLogxK

U2 - 10.1002/ijc.25395

DO - 10.1002/ijc.25395

M3 - Article

C2 - 20473885

AN - SCOPUS:78650617304

VL - 128

SP - 763

EP - 770

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -